News
04-23-2010, 12:01 AM
Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.
More... (http://www.news-medical.net/news/20100423/Genentech-submits-sBLA-for-Herceptin-plus-chemotherapy-for-advanced-HER2-positive-stomach-cancer.aspx)
More... (http://www.news-medical.net/news/20100423/Genentech-submits-sBLA-for-Herceptin-plus-chemotherapy-for-advanced-HER2-positive-stomach-cancer.aspx)